,25 Sudhan and colleagues further demonstrated that treatment with everolimus, an mTOR inhibitor, was able to overcome resistance by restoring ErbB2-mutant tumor cell sensitivity to neratinib. The gene discussed is ERBB2; the disease is neoplasm.